Concepedia

Publication | Open Access

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse

DOIFull Paper Access

27

Citations

20

References

2022

Year

Ibiayi Dagogo‐Jack, Geoffrey R. Oxnard, Makenzi Colleen Evangelist, Subba R. Digumarthy, Justin F. Gainor, John F. Murphy, Michael S. Rabin, Rebecca S. Heist, Alona Muzikansky, Alice T. Shaw
JCO Precision Oncology

Abstract

Lorlatinib induced durable intracranial disease control in patients with CNS-only relapse on second-generation ALK inhibitors, suggesting that tumors with CNS-limited progression on brain-penetrant ALK tyrosine kinase inhibitors remain ALK-dependent.

References

YearCitations

Page 1